Instil Bio

Contributing Author

Recent Articles by Instil Bio

May-23	Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago TIL -14.59% GlobeNewswire
May-22	Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 ('2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025 TIL GlobeNewswire
May-13	Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update TIL GlobeNewswire